V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 220020735 | 220007718 | 1.68 | 74.1 | Adjuvant (A) | 2014-10-18 | 2015-01-31 | Triple / Double Intrathecal Therapy | N | N | 220029749 | TRIPLE INTRATHECAL |
| 220020736 | 220007724 | 1.78 | 133.6 | Disease modification (D) | 2016-01-13 | 2016-01-13 | BOSUTINIB | N | N | 220029760 | BOSUTINIB |
| 220020737 | 220007730 | 1.85 | 87.3 | Not known (9) | 2016-03-22 | 2016-03-22 | BOSUTINIB | N | null | 220029771 | BOSUTINIB |
| 220020738 | 220007745 | 1.7 | 83.7 | Disease modification (D) | 2016-05-26 | 2016-05-26 | AML16 DA 3+8 | N | N | 220029817 | AML16 TRIAL |
| 220020741 | 220007771 | 1.63 | 87 | Curative (C) | 2018-09-06 | 2018-09-13 | FLAG | 2 | N | 220029903 | FLAG |
| 220020742 | 220007776 | 1.84 | 109.1 | null | null | 2018-06-18 | Cyclophosphamide+Fludara+TBI Allo | 2 | N | 220029943 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 220020743 | 220007790 | 1.58 | 39.8 | Curative (C) | 2015-06-01 | 2015-06-01 | CYCLOPHOSPHAMIDE + FLUDARABINE | 02 | N | 220029989 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 220020744 | 220007799 | 1.68 | 75 | Curative (C) | 2016-09-30 | 2016-10-03 | Cyclophosphamide+Fludara+TBI Allo | N | N | 220030038 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 220020745 | 220007804 | null | null | Palliative (P) | 2017-03-17 | 2017-07-07 | Idarubicin+Tretinoin Spanish Crse4 | N | N | 220030047 | IDARUBICIN + TRETINOIN |
| 220020746 | 220007815 | 1.74 | 79.9 | Curative (C) | 2018-04-25 | 2018-05-15 | ATG + Busulfan + Fludarabine | N | N | 220030066 | ATG + BUSULFAN + FLUDARABINE |
| 220020747 | 220017804 | 1.74 | 60 | Curative (C) | 2017-07-27 | 2017-08-01 | Cyclophosphamide TBI Allograft | 2 | N | 220030089 | CYCLOPHOSPHAMIDE |
| 220020748 | 220007824 | 1.62 | null | Disease modification (D) | null | 2016-08-11 | BOSUTINIB | N | null | 220030093 | BOSUTINIB |
| 220020749 | 220007829 | 1.91 | 97.8 | Curative (C) | 2013-09-17 | 2014-04-30 | Idarubicin+Tretinoin Spanish Crse4 | Y | N | 220030109 | IDARUBICIN + TRETINOIN |
| 220020750 | 220014310 | 0 | 105.5 | Curative (C) | 2016-05-03 | 2016-05-03 | CYCLOPHOSPHAMIDE | N | N | 220030114 | CYCLOPHOSPHAMIDE |
| 220020751 | 220014314 | 1.67 | null | Disease modification (D) | 2015-10-14 | 2015-10-15 | ATG + Busulfan + Fludarabine | N | N | 220030142 | ATG + BUSULFAN + FLUDARABINE |
| 220020752 | 220007838 | 1.51 | 50.6 | Curative (C) | 2015-12-01 | 2015-12-01 | CYCLOPHOSPHAMIDE | N | null | 220030144 | CYCLOPHOSPHAMIDE |
| 220020753 | 220007843 | 1.62 | 67 | Curative (C) | 2014-03-10 | 2014-03-14 | AML Int Guide ADE 8+3+5 (2) | 02 | N | 220030145 | ADE |
| 220020754 | 220007846 | null | 67 | Disease modification (D) | 2018-12-24 | 2018-12-26 | CYCLOPHOSPHAMIDE | null | N | 220030148 | CYCLOPHOSPHAMIDE |
| 220020755 | 220007853 | 1.72 | 67 | Curative (C) | 2018-10-18 | 2019-04-18 | CYCLOPHOSPHAMIDE + FLUDARABINE | N | N | 220030168 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 220020756 | 220007857 | 1.57 | 79.9 | Disease modification (D) | 2017-02-28 | 2017-03-07 | ATG + Busulfan + Fludarabine | N | N | 220030182 | ATG + BUSULFAN + FLUDARABINE |
| 220020757 | 220007862 | 1.8 | 76 | Palliative (P) | 2018-10-04 | 2018-10-15 | AML16 DA 3+8 | N | N | 220030188 | AML16 TRIAL |
| 220020758 | 220007874 | 1.51 | 65.7 | Curative (C) | 2017-07-13 | 2017-07-14 | FLAG | 02 | N | 220030225 | FLAG |
| 220020759 | 220007880 | 1.57 | null | Palliative (P) | 2017-01-01 | 2017-07-13 | BOSUTINIB | N | N | 220030233 | BOSUTINIB |
| 220020761 | 220014336 | 1.66 | 75 | Curative (C) | 2016-03-09 | 2016-09-22 | Idarubicin+Tretinoin Spanish Crse4 | N | N | 220030293 | IDARUBICIN + TRETINOIN |
| 220020762 | 220007906 | 1.53 | 54.6 | Disease modification (D) | 2017-06-06 | 2017-06-10 | BOSUTINIB | N | N | 220030299 | BOSUTINIB |
| 220020763 | 220007916 | 1.66 | null | Curative (C) | 2016-02-02 | 2016-02-05 | CYCLOPHOSPHAMIDE + FLUDARABINE | N | N | 220030316 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 220020764 | 220007924 | 1.56 | 71.45 | Disease modification (D) | 2015-09-23 | 2015-09-30 | FLAG | N | N | 220030337 | FLAG |
| 220020765 | 220017824 | null | null | Curative (C) | 2013-10-04 | 2014-02-02 | Triple / Double Intrathecal Therapy | 02 | N | 220030339 | TRIPLE INTRATHECAL |
| 220020766 | 220007929 | 1.75 | 55 | Curative (C) | 2013-12-31 | 2014-01-01 | Methotrexate intrathecal | N | N | 220030353 | METHOTREXATE INTRATHECAL |
| 220020767 | 220014353 | 1.64 | 60.3 | Disease modification (D) | 2015-07-23 | 2015-07-23 | Idarubicin+Tretinoin Spanish Crse4 | 02 | N | 220030395 | IDARUBICIN + TRETINOIN |
| 220020768 | 220017833 | 1.69 | null | Curative (C) | 2017-10-05 | 2017-12-06 | RUXOLITINIB | N | N | 220030435 | RUXOLITINIB |
| 220020769 | 220007956 | 0 | 0 | Curative (C) | 2017-07-30 | 2017-08-02 | FLAG | 2 | N | 220030458 | FLAG |
| 220020770 | 220007960 | null | 56.7 | Curative (C) | 2015-03-10 | 2015-04-12 | Triple / Double Intrathecal Therapy | N | N | 220030471 | TRIPLE INTRATHECAL |
| 220020771 | 220017839 | 1.7 | null | Disease modification (D) | 2018-08-13 | 2018-08-20 | Idarubicin+Tretinoin Spanish Crse1 | N | N | 220030475 | IDARUBICIN + TRETINOIN |
| 220020772 | 220017841 | 1.62 | 67.6 | Curative (C) | 2018-03-01 | 2018-03-01 | FLAG | 02 | null | 220030478 | FLAG |
| 220020773 | 220007979 | 1.86 | 105 | Curative (C) | 2014-10-12 | 2015-02-10 | AML16 LD Clofarabine | N | N | 220030495 | AML16 TRIAL |
| 220020774 | 220014377 | 1.52 | 53.3 | Curative (C) | 2014-05-06 | 2014-05-17 | IDARUBICIN + TRETINOIN | N | N | 220030497 | IDARUBICIN + TRETINOIN |
| 220020775 | 220007992 | 1.77 | null | Disease modification (D) | null | 2014-02-11 | BOSUTINIB | N | N | 220030524 | BOSUTINIB |
| 220020776 | 220007996 | null | 10 | Curative (C) | 2014-02-14 | 2015-01-29 | Triple Intrathecal | N | null | 220030530 | TRIPLE INTRATHECAL |
| 220020777 | 220008000 | null | null | Disease modification (D) | 2016-08-22 | 2016-08-29 | ATG + Busulfan + Fludarabine | 99 | N | 220030535 | ATG + BUSULFAN + FLUDARABINE |
| 220020778 | 220008006 | 1.59 | 29 | Curative (C) | 2014-09-14 | 2016-03-10 | BOSUTINIB | 2 | N | 220030541 | BOSUTINIB |
| 220020779 | 220008012 | 1.67 | 0 | Curative (C) | 2015-01-12 | 2015-03-25 | FLAG | N | N | 220030561 | FLAG |
| 220020780 | 220014390 | 1.79 | null | Curative (C) | 2017-10-23 | 2017-10-23 | AML Int Guide ADE 8+3+5 (2) | 2 | N | 220030565 | ADE |
| 220020781 | 220014398 | 1.5 | 75.6 | Curative (C) | 2016-08-14 | 2016-08-17 | Triple Intrathecal | 2 | N | 220030624 | TRIPLE INTRATHECAL |
| 220020782 | 220014399 | null | 90 | Disease modification (D) | 2015-01-29 | 2015-03-18 | ATG + Busulfan + Fludarabine | N | N | 220030630 | ATG + BUSULFAN + FLUDARABINE |
| 220020783 | 220014402 | 1.84 | 71.8 | Curative (C) | 2018-07-20 | 2018-09-10 | ATG + Busulfan + Fludarabine | 2 | N | 220030653 | ATG + BUSULFAN + FLUDARABINE |
| 220020784 | 220008046 | 1.56 | null | Curative (C) | 2013-08-24 | 2013-09-01 | IDARUBICIN + TRETINOIN | null | null | 220030661 | IDARUBICIN + TRETINOIN |
| 220020785 | 220008050 | 1.73 | 66.2 | Curative (C) | 2016-01-31 | 2016-01-31 | ATG + Busulfan + Fludarabine | N | N | 220030685 | ATG + BUSULFAN + FLUDARABINE |
| 220020786 | 220008052 | 1.84 | 20 | Disease modification (D) | 2013-05-15 | 2013-05-20 | RUXOLITINIB | 02 | N | 220030691 | RUXOLITINIB |
| 220020787 | 220008078 | 1.65 | 70 | Curative (C) | null | 2016-01-31 | IDARUBICIN + TRETINOIN | N | N | 220030743 | IDARUBICIN + TRETINOIN |